Atomo Diagnostics Ltd (ASX:AT1)

Full Year 2025 Atomo Diagnostics Ltd Earnings Call Transcript

Sep 1, 2025 / 01:00 AM GMT

Release Date Price: A$0.019

Transcript

Key Points

Positve

Atomo Diagnostics Ltd (ASX:AT1) achieved a revenue of 3.8 million, maintaining stability compared to the prior year.
The company improved its gross margin from 39% to over 50% in FY25, reflecting a focus on higher-margin markets.
Significant progress was made in the development of a syphilis test, which complements the existing HIV testing channels.
The Pascal platform has been instrumental in securing clear waiver processes in the US, opening up significant revenue opportunities.
The company successfully raised just under $3 million, primarily supported by existing shareholders, indicating strong investor confidence.

Negative

HIV sales decreased due to a reduction in global health funding from the US, impacting top-line revenue.
Operating expenses, although reduced, still resulted in a net cash outflow, reflecting ongoing financial challenges.
The company is still not profitable, with a loss of just under 3.5 million, despite improvements.
The transition away from reliance on global health volume presents a challenge in maintaining revenue growth.
The development and commercialization of new products, such as the syphilis test, require significant investment and regulatory approval, posing potential delays.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AT1.AX - Atomo Diagnostics Ltd
Full Year 2025 Atomo Diagnostics Ltd Earnings Call
Sep 02, 2025 / 01:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Diagnostics and we're here today. I'm joined with our financial controller, Susie Ilu for our FI25 results presentation. And thank you for joining us. By way of an introduction for anyone who's who's new to Otamo or the story, I just wanted to take a moment to talk about, who Atamo is and what we do. We're an innovator in point of care diagnostics. And we're an Australian-based company with low cost operations overseas that allow us to be competitive in international point of care rapid test markets. We've developed a range of patented portfolio products that really move the dial in terms of usability and ease of use in point of care testing, primarily blood testing. And our techno technology is now increasingly recognized

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.